Skip Navigation


NDT Plus Advance Access originally published online on September 19, 2009
NDT Plus 2009 2(6):512-513; doi:10.1093/ndtplus/sfp134
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2/6/512    most recent
sfp134v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kurita, N.
Right arrow Articles by Sugimoto, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press [on behalf of ERA-EDTA]. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Crescentic glomerulonephritis in a patient with advanced lung cancer during erlotinib therapy

Noriaki Kurita1, Naobumi Mise1, Akiko Fujii2, Shingo Ikeda3 and Tokuichiro Sugimoto1

1 Department of Medicine
2 Department of Pathology
3 Department of Respiratory Surgery, Mitsui Memorial Hospital Tokyo, Japan E-mail: kurita-noriaki@mitsuihosp.or.jp

The first 10% of the full text of this article appears below.

Sir,

Erlotinib (Tarceva®), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been shown to improve survival of previously treated non-small cell lung cancer (NSCLC) [1]. The common adverse effects of this agent include diarrhoea and anorexia [1], which may cause severe dehydration and renal failure, although their incidence has been low [2]. Here, . . . [Full Text of this Article]


   Case
 

   Discussion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?